Royalty Pharma PLC
Royalty Pharma's GHG Emissions Data Preview
In 2023, Royalty Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 3 (indirect emissions across the value chain).
Royalty Pharma has also provided a category-level breakdown for 1 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2023 | 2022 | 2021 | 2020 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Location-Based | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Create your Tracenable account today and download up to 5 company datasets of your choice for free. No credit card required.
Verified Sources Behind Royalty Pharma’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Royalty Pharma’s data sources below and access millions more through our Disclosure Search.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.
Insights into Royalty Pharma's Operational Emissions
No operational GHG emissions data disclosed for Royalty Pharma in 2023.
Insights into Royalty Pharma's Value Chain Emissions
In 2023, Royalty Pharma reported 32,002 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain. a
The 2023 disclosure of Royalty Pharma includes a breakdown across 1 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2022, demonstrating consistent Scope 3 emissions reporting coverage year over year. a
Royalty Pharma's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Royalty Pharma's Scope 3 emissions?
In 2023, Royalty Pharma reported total Scope 3 emissions of 32,002 metric tons of CO₂ equivalent (tCO₂e). a
Approximately 0% of these emissions originated from upstream activities such as purchased goods and capital goods, while 100% came from downstream activities like product use, distribution, and end-of-life treatment. a
Has Royalty Pharma reduced its Scope 3 emissions over time?
Since 2021, Royalty Pharma's Scope 3 emissions have increased by 73.5%, reflecting a rising long-term trend in Scope 3 emissions over time. a
Compared to the previous year (2022), Royalty Pharma's Scope 3 emissions increased by 63.19%, suggesting that the company faced challenges in reducing emissions across its value chain. a
What categories of Scope 3 emissions does Royalty Pharma disclose?
In 2023, Royalty Pharma reported emissions for 1 out of the 15 Scope 3 categories defined by the GHG Protocol. a
The limited disclosure restricts visibility into specific emission sources across the company's value chain.
What are the main sources of Royalty Pharma's Scope 3 emissions?
In 2023, the largest contributors to Royalty Pharma's Scope 3 emissions were: a
- Investments (Cat. 15): 32,002 tCO₂e (100%)